U.S. Markets close in 5 hrs 37 mins

What Could Drive Amgen’s Long-Term Growth?

Daniel Collins
What Could Drive Amgen’s Long-Term Growth?

In January 2018, the European Commission (or EC) approved Amgen’s (AMGN) and Allergan’s (AGN) Marketing Authorization Application (or MAA) for Mvasi, a biosimilar to Roche’s (RHHBY) Avastin (bevacizumab). Amgen’s Mvasi became the first bevacizumab biosimilar to be approved by the EC for the treatment of particular types of cancer. In January 2018, Amgen presented positive results from its Phase 3b LIBERTY trial.